Novo Nordisk

Novo Nordisk. Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark, renowned as a world leader in diabetes care. The company also has leading positions within other serious chronic diseases including obesity, haemophilia, and growth disorders. Its history dates to the 1920s in Scandinavia, evolving from two separate Danish companies that merged in 1989.

History

The company's origins trace back to 1923 when August Krogh and his wife Marie Krogh, inspired by Canadian discoveries, began producing insulin in Denmark under the name Nordisk Insulinlaboratorium. The following year, brothers Harald Pedersen and Thorvald Pedersen founded Novo Terapeutisk Laboratorium to manufacture insulin, initiating a decades-long rivalry. Throughout the mid-20th century, both companies were instrumental in pioneering longer-acting insulin formulations, with Nordisk's Hans Christian Hagedorn developing NPH insulin. Novo introduced the first monocomponent insulin in the 1970s. The two entities merged in 1989 to form the present company, creating a powerhouse in biotechnology. Key milestones since the merger include the introduction of modern analog insulin like insulin aspart and the expansion into treatments for obesity and other endocrine conditions.

Products

The company's portfolio is dominated by therapies for diabetes mellitus, including a wide range of insulin products such as Levemir, NovoRapid, and Tresiba. Its GLP-1 receptor agonist class drugs, such as Victoza and Ozempic, have become blockbuster treatments for type 2 diabetes. Notably, the GLP-1 medication semaglutide, marketed as Wegovy, is approved specifically for chronic weight management in obesity. Beyond metabolic diseases, the company produces treatments for haemophilia (like NovoSeven), hormone replacement therapy (including Vagifem), and growth hormone deficiency (with Norditropin). These products are marketed globally, with major operations in North America, Europe, and Asia.

Research and development

Research efforts are intensely focused on advancing care for serious chronic diseases, with major centers located in Denmark, the U.S., and China. The core of its pipeline involves next-generation therapies for diabetes and obesity, including novel GLP-1 and GIP receptor agonists and combinations. The company is investing heavily in cardiovascular disease outcomes research linked to its metabolic drugs, following landmark trials like LEADER and SUSTAIN 6. Additional R&D areas include haemophilia treatments using factor VIIa and factor VIII technologies, NASH (non-alcoholic steatohepatitis), and Alzheimer's disease. Collaborations with academic institutions like the University of Oxford and biotech firms are central to its innovation strategy.

Corporate affairs

The company operates under a unique corporate governance structure with a dual-class share system, controlled by the Novo Nordisk Foundation, one of the world's largest philanthropic foundations. The foundation's charter ensures a portion of dividends supports scientific, humanitarian, and social causes. The executive management is led by CEO Lars Fruergaard Jørgensen, with Helge Lund serving as Chairman of the board. It is a publicly listed company on the Nasdaq Copenhagen and the New York Stock Exchange. Its commercial success, particularly in the United States, has made it the most valuable company in Europe by market capitalization, significantly impacting the Danish economy.

Environmental and social responsibility

The company's sustainability strategy, "Circular for Zero," aims for zero environmental impact by radically reducing waste and carbon emissions across its value chain. It is committed to powering all production sites with renewable energy by 2030. Socially, through the Novo Nordisk Foundation, it provides extensive funding for biomedical research at institutions like the Novo Nordisk Foundation Center for Basic Metabolic Research. The company runs global access programs, such as the Changing Diabetes initiative, to improve diabetes care in disadvantaged regions including parts of Africa and South Asia. It actively promotes diversity and inclusion within its workforce and adheres to strict bioethics standards in its clinical trials.